CVAC Quote, Financials, Valuation and Earnings

Evotec SE has a net margin of -5832.47% compared to CureVac NV's net margin of -26.29%. CureVac NV's return on equity of 20.55% beat Evotec SE's return on equity of -17.7%.

CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 3.97%. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 69.18%. Given that Evotec SE has higher upside potential than CureVac NV, analysts believe Evotec SE is more attractive than CureVac NV.

CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $63.3M, which are smaller than Evotec SE quarterly revenues of $191.5M. CureVac NV's net income of $319.3M is higher than Evotec SE's net income of -$50.3M. Notably, CureVac NV's price-to-earnings ratio is 7.16x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 14.22x versus 1.38x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -5832.47% compared to CureVac NV's net margin of -51538.49%. CureVac NV's return on equity of 20.55% beat InflaRx NV's return on equity of -82.01%.

CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 3.97%. On the other hand InflaRx NV has an analysts' consensus of $11.64 which suggests that it could grow by 1041.22%. Given that InflaRx NV has higher upside potential than CureVac NV, analysts believe InflaRx NV is more attractive than CureVac NV.

CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $63.3M, which are larger than InflaRx NV quarterly revenues of $27.8K. CureVac NV's net income of $319.3M is higher than InflaRx NV's net income of -$14.3M. Notably, CureVac NV's price-to-earnings ratio is 7.16x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 14.22x versus 315.16x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -5832.47% compared to CureVac NV's net margin of -974.45%. CureVac NV's return on equity of 20.55% beat Immatics NV's return on equity of -25.21%.

CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 3.97%. On the other hand Immatics NV has an analysts' consensus of $18.63 which suggests that it could grow by 80.13%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.

CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $63.3M, which are larger than Immatics NV quarterly revenues of $6.1M. CureVac NV's net income of $319.3M is higher than Immatics NV's net income of -$59.1M. Notably, CureVac NV's price-to-earnings ratio is 7.16x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 14.22x versus 13.81x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.

Anbio Biotechnology has a net margin of -5832.47% compared to CureVac NV's net margin of --. CureVac NV's return on equity of 20.55% beat Anbio Biotechnology's return on equity of --.

CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 3.97%. On the other hand Anbio Biotechnology has an analysts' consensus of -- which suggests that it could fall by --. Given that CureVac NV has higher upside potential than Anbio Biotechnology, analysts believe CureVac NV is more attractive than Anbio Biotechnology.

CureVac NV has a beta of 1.771, which suggesting that the stock is 77.063% more volatile than S&P 500. In comparison Anbio Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anbio Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Anbio Biotechnology pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $63.3M, which are larger than Anbio Biotechnology quarterly revenues of --. CureVac NV's net income of $319.3M is higher than Anbio Biotechnology's net income of --. Notably, CureVac NV's price-to-earnings ratio is 7.16x while Anbio Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 14.22x versus 164.94x for Anbio Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.